| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 2.77 | 91.0% |
| Total Income | 2.77 | 91.0% |
| Expenditure | 28.15 | 57.3% |
| PBT | — | |
| Net Profit | -22.25 | 72.1% |
| OPM | — | |
| NPM | — | |
| EPS | -0.52 | 44.4% |
BioAge Labs Reports First Quarter 2026 Financial Results
08 May 2026 · 8 May, 6:46 pm
Summary
BioAge Labs reported its first quarter 2026 financial results, highlighting positive topline Phase 1 data for BGE-102 and plans to initiate Phase 2 trials. The company completed an upsized follow-on public offering of $132.3 million. Collaboration revenue increased to $2.8 million from $1.5 million year-over-year, driven by the Novartis collaboration. The net loss for the quarter was $22.3 million, or $0.52 per share, compared to a net loss of $12.9 million, or $0.36 per share, in the prior year. BioAge estimates that its existing cash and cash equivalents will be sufficient to fund operations and capital expenses through 2029.
Key Highlights
- 1
BioAge Labs reported positive topline Phase 1 data for BGE-102, showing potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk.
- 2
The company plans to initiate a Phase 2 dose-ranging proof-of-concept trial of BGE-102 in cardiovascular risk in mid-2026, with data anticipated by the end of the year.
- 3
A Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema is planned to start in mid-2026, with data expected in mid-2027.
- 4
BioAge completed an upsized follow-on public offering of $132.3 million.
- 5
Collaboration revenue was $2.8 million for the quarter ended March 31, 2026, compared to $1.5 million for the same period in 2025.
- 6
Net loss was $22.3 million for the quarter ended March 31, 2026, or $0.52 per share, compared to a net loss of $12.9 million, or $0.36 per share, for the same period in 2025.
- 7
As of March 31, 2026, BioAge had approximately $384.9 million in cash, cash equivalents, and marketable securities.
Management Comments
Kristen Fortney
Ph.D.
"The positive topline Phase 1 data we reported for BGE-102 in April reinforce our conviction that we have a potential best-in-class NLRP3 inhibitor: a well-tolerated, once-daily oral therapy that could deliver the anti-inflammatory efficacy of injectables. Our focus now is execution. We plan to initiate two BGE-102 proof-of-concept trials by mid-2026 — a Phase 2 dose-ranging trial in cardiovascular risk, and a Phase 1b/2a trial in diabetic macular edema — advancing BGE-102 as a potential 'pipeline in a pill' across cardiometabolic and ocular diseases. With the $132.3 million we raised in our upsized follow-on offering earlier this year, we have the capital to drive both programs through key milestones."
Informational and educational content only. Not investment advice.